{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:03:35Z","timestamp":1792728215919,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T00:00:00Z","timestamp":1486684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajkd.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1053\/j.ajkd.2016.12.011","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T08:48:54Z","timestamp":1488185334000},"page":"815-826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":404,"title":["Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A\u00a0Potential New Treatment for Anemia in Patients With CKD"],"prefix":"10.1053","volume":"69","author":[{"given":"Nupur","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay B.","family":"Wish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.ajkd.2016.12.011_bib1","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.1128\/MCB.12.12.5447","article-title":"A\u00a0nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1053\/j.ajkd.2016.12.011_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/glycob\/1.4.337","article-title":"Structures and functional roles of the sugar chains of human erythropoietins","volume":"1","author":"Takeuchi","year":"1991","journal-title":"Glycobiology"},{"issue":"3","key":"10.1053\/j.ajkd.2016.12.011_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00000441-198809000-00005","article-title":"Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial","volume":"296","author":"Stone","year":"1988","journal-title":"Am J Med Sci"},{"issue":"20","key":"10.1053\/j.ajkd.2016.12.011_bib4","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2016.12.011_bib5","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2016.12.011_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.ajkd.2015.06.030","article-title":"New treatment approaches for the anemia of CKD","volume":"67","author":"Bonomini","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2016.12.011_bib7","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5516","key":"10.1053\/j.ajkd.2016.12.011_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"issue":"5516","key":"10.1053\/j.ajkd.2016.12.011_bib9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"issue":"44","key":"10.1053\/j.ajkd.2016.12.011_bib10","doi-asserted-by":"crossref","first-page":"33756","DOI":"10.1074\/jbc.M110.132985","article-title":"Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA\/rho-associated kinase-dependent cofilin phosphorylation","volume":"285","author":"Vogel","year":"2010","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"10.1053\/j.ajkd.2016.12.011_bib11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cell.2015.03.011","article-title":"A\u00a0lactate-induced response to hypoxia","volume":"161","author":"Lee","year":"2015","journal-title":"Cell"},{"issue":"5556","key":"10.1053\/j.ajkd.2016.12.011_bib12","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.1068592","article-title":"Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch","volume":"295","author":"Lando","year":"2002","journal-title":"Science"},{"issue":"12","key":"10.1053\/j.ajkd.2016.12.011_bib13","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1101\/gad.991402","article-title":"FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor","volume":"16","author":"Lando","year":"2002","journal-title":"Genes Dev"},{"issue":"9","key":"10.1053\/j.ajkd.2016.12.011_bib14","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.yexcr.2012.02.035","article-title":"Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents","volume":"318","author":"Tanaka","year":"2012","journal-title":"Exp Cell Res"},{"issue":"7","key":"10.1053\/j.ajkd.2016.12.011_bib15","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/01.ASN.0000017223.49823.2A","article-title":"Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys","volume":"13","author":"Rosenberger","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2016.12.011_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C.\u00a0elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell"},{"issue":"18","key":"10.1053\/j.ajkd.2016.12.011_bib17","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1093\/emboj\/20.18.5197","article-title":"Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation","volume":"20","author":"Masson","year":"2001","journal-title":"EMBO J"},{"issue":"22","key":"10.1053\/j.ajkd.2016.12.011_bib18","doi-asserted-by":"crossref","first-page":"8336","DOI":"10.1128\/MCB.00425-06","article-title":"Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2","volume":"26","author":"Takeda","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"7","key":"10.1053\/j.ajkd.2016.12.011_bib19","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.107.701516","article-title":"Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system","volume":"116","author":"Takeda","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1053\/j.ajkd.2016.12.011_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.blre.2009.09.001","article-title":"Anemia in renal disease: diagnosis and management","volume":"24","author":"Lankhorst","year":"2010","journal-title":"Blood Rev"},{"issue":"16","key":"10.1053\/j.ajkd.2016.12.011_bib21","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood-2010-02-270322","article-title":"Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia","volume":"116","author":"Kapitsinou","year":"2010","journal-title":"Blood"},{"issue":"32","key":"10.1053\/j.ajkd.2016.12.011_bib22","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","article-title":"Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1","volume":"272","author":"Rolfs","year":"1997","journal-title":"J\u00a0Biol Chem"},{"issue":"21","key":"10.1053\/j.ajkd.2016.12.011_bib23","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1093\/nar\/27.21.4223","article-title":"HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation","volume":"27","author":"Bianchi","year":"1999","journal-title":"Nucleic Acids Res"},{"issue":"34","key":"10.1053\/j.ajkd.2016.12.011_bib24","doi-asserted-by":"crossref","first-page":"24142","DOI":"10.1074\/jbc.274.34.24142","article-title":"Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation","volume":"274","author":"Tacchini","year":"1999","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1053\/j.ajkd.2016.12.011_bib25","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1053\/j.ajkd.2016.12.011_bib26","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI31370","article-title":"Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)","volume":"117","author":"Peyssonnaux","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1053\/j.ajkd.2016.12.011_bib27","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1053\/j.ajkd.2016.12.011_bib28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.stem.2010.06.020","article-title":"Regulation of the HIF-1alpha level is essential for hematopoietic stem cells","volume":"7","author":"Takubo","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1053\/j.ajkd.2016.12.011_bib29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2012-02-408419","article-title":"Pharmacologic stabilization of HIF-1alpha increases hematopoietic stem cell quiescence in\u00a0vivo and accelerates blood recovery after severe irradiation","volume":"121","author":"Forristal","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.ajkd.2016.12.011_bib30","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2016.12.011_bib31","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2016.12.011_bib32","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2016.12.011_bib33","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2016.12.011_bib34","first-page":"761A","article-title":"Novel and beneficial pharmacodynamic properties of endogenous EPO and \u2018complete erythropoiesis\u2019 induced by selective HIF prolyl hydroxylase inhibitors","volume":"16","author":"Seeley","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2016.12.011_bib35","first-page":"524A","article-title":"Beneficial pharmacodynamic effects resulting from \u2018complete erythropoiesis\u2019 induced by novel HIF prolyl hydroxylase inhibitors FG-2216 and FG-4592","volume":"19","author":"Klaus","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2016.12.011_bib36","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nrd4422","article-title":"Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases","volume":"13","author":"Eltzschig","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.ajkd.2016.12.011_bib37","first-page":"95A","article-title":"FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3\/4 CKD patients","volume":"21","author":"Besarab","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2016.12.011_bib38","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40261-016-0422-y","article-title":"Effect of moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor","volume":"36","author":"Groenendaal-van de Meent","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1053\/j.ajkd.2016.12.011_bib39","first-page":"21A","article-title":"FG-4592, an oral hypoxia-inducible factor prolyl hydroxylase-inhibitor, corrects anemia without iron supplementation in incident dialysis patients","volume":"23","author":"Besarab","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2016.12.011_bib40","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2016.12.011_bib41","article-title":"TH-OR039 anemia correction with roxadustat improves health related quality of life (HRQOL) in chronic kidney disease (CKD) patients","author":"Szczech","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2016.12.011_bib42","article-title":"TH-PO648 anemia correction with roxadustat lowers cholesterol in chronic kidney disease (CKD) patients","author":"Szczech","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2016.12.011_bib43","first-page":"45A","article-title":"AKB-6548, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor reduces hepcidin and ferritin while it increases reticulocyte production and total iron binding capacity in healthy adults","volume":"22","author":"Shalwitz","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2016.12.011_bib44","first-page":"56A","article-title":"AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin in chronic kidney disease patients without increasing basal erythropoietin levels","volume":"23","author":"Shalwitz","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2016.12.011_bib45","first-page":"435A","article-title":"AK-6548 a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia","volume":"22","author":"Hartman","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2016.12.011_bib46","first-page":"B8","article-title":"Vadadustat, a novel, oral treatment for anemia of chronic kidney disease, maintains stable hemoglobin levels in dialysis patients converting from erythropoiesis-stimulating agents [abstract]","volume":"26","author":"Haase","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2016.12.011_bib47","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.dmpk.2015.08.004","article-title":"Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects","volume":"30","author":"Hara","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"10.1053\/j.ajkd.2016.12.011_bib48","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2016.12.011_bib49","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A\u00a0novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2016.12.011_bib50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/cpdd.83","article-title":"Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863","volume":"3","author":"Johnson","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11","key":"10.1053\/j.ajkd.2016.12.011_bib51","doi-asserted-by":"crossref","first-page":"e111838","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PloS One"},{"key":"10.1053\/j.ajkd.2016.12.011_bib52","first-page":"347A","article-title":"First-in-man study with BAY 85-3934\u2014a new oral selective HIF-PH inhibitor for the treatment of renal anemia","volume":"24","author":"Boettcher","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2016.12.011_bib53","first-page":"i15","article-title":"Molidustat increases hemoglobin in erythropoiesis stimulating agents (ESA) - naive anaemic patients with chronic kidney diseases not on dialysis (CKD-ND)","volume":"31","author":"Macdougall","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2016.12.011_bib54","unstructured":"Amgen. ARANESP\u00ae (darbepoetin alfa) injection, for intravenous or subcutaneous use. http:\/\/pi.amgen.com\/united_states\/aranesp\/ckd\/aranesp_pi_hcp_english.pdf. Accessed February 14, 2017."},{"key":"10.1053\/j.ajkd.2016.12.011_bib55","unstructured":"Amgen. Epogen\u00ae (epoetin alfa) injection, for intravenous or subcutaneous use. http:\/\/pi.amgen.com\/united_states\/epogen\/epogen_pi_hcp_english.pdf. Accessed February 14, 2017."},{"issue":"1","key":"10.1053\/j.ajkd.2016.12.011_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000245041","article-title":"Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management","volume":"29","author":"Kanbay","year":"2010","journal-title":"Blood Purif"},{"issue":"4","key":"10.1053\/j.ajkd.2016.12.011_bib57","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1373\/clinchem.2014.229179","article-title":"Hepcidin and the global burden of iron deficiency","volume":"61","author":"Ganz","year":"2015","journal-title":"Clin Chem"},{"issue":"9","key":"10.1053\/j.ajkd.2016.12.011_bib58","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ki.2009.21","article-title":"Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease","volume":"75","author":"Ashby","year":"2009","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2016.12.011_bib59","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/1744-9987.12322","article-title":"Effects of long-term erythropoiesis-stimulating agents on iron metabolism in patients on hemodialysis","volume":"19","author":"Onuma","year":"2015","journal-title":"Ther Apher Dial"},{"issue":"11","key":"10.1053\/j.ajkd.2016.12.011_bib60","doi-asserted-by":"crossref","first-page":"e7875","DOI":"10.1371\/journal.pone.0007875","article-title":"Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors","volume":"4","author":"Volke","year":"2009","journal-title":"PloS One"},{"issue":"7","key":"10.1053\/j.ajkd.2016.12.011_bib61","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat Genet"},{"issue":"12","key":"10.1053\/j.ajkd.2016.12.011_bib62","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1053\/j.ajkd.2016.12.011_bib63","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1177\/1947601911423654","article-title":"Hypoxia-induced angiogenesis: good and evil","volume":"2","author":"Krock","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1053\/j.ajkd.2016.12.011_bib64","first-page":"196A","article-title":"FG-4592 Oralhypoxia-inducible factor prolyl hydroxylase inhibitor corrects anemia in nondialysis CKD patients without IV iron","volume":"22","author":"Besarab","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2016.12.011_bib65","article-title":"FR-OR011 A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China","author":"Qian","year":"2013","journal-title":"JASN Kidney Week"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2016.12.011_bib66","doi-asserted-by":"crossref","first-page":"ii21","DOI":"10.1093\/ndt\/gfu117","article-title":"SO048 IV ferric carboxymaltose (FCM) is a convenient and well-tolerated first-line therapy for the treatment of anaemia in patients with iron deficiency and non-dialysis dependent chronic kidney disease (ND-CKD): results of the randomised find-CKD study","author":"Roger","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 26","key":"10.1053\/j.ajkd.2016.12.011_bib67","first-page":"818A","article-title":"SA-P0819 A 4-week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic hemodialysis subjects","author":"Endo","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2016.12.011_bib68","article-title":"SP309 Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract]","volume":"31","author":"Macdougall","year":"2016","journal-title":"Nephrol Dial Transplant"}],"updated-by":[{"DOI":"10.1053\/j.ajkd.2017.04.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000}}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617301105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617301105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T03:52:32Z","timestamp":1568865152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638617301105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0272638617301105"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.12.011","relation":{"erratum":[{"id-type":"doi","id":"10.1053\/j.ajkd.2017.04.001","asserted-by":"object"}]},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A\u00a0Potential New Treatment for Anemia in Patients With CKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2016.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}